Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis

被引:163
|
作者
Matsushita, Takuya [1 ]
Tateishi, Takahisa [1 ]
Isobe, Noriko [1 ]
Yonekawa, Tomomi [1 ]
Yamasaki, Ryo [2 ]
Matsuse, Dai [1 ]
Murai, Hiroyuki [1 ]
Kira, Jun-ichi [1 ]
机构
[1] Kyushu Univ, Dept Neurol, Neurol Inst, Grad Sch Med Sci, Fukuoka 812, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Neurol Therapeut, Neurol Inst, Fukuoka 812, Japan
来源
PLOS ONE | 2013年 / 8卷 / 04期
关键词
T-HELPER TYPE-1; RHEUMATOID-ARTHRITIS; DIAGNOSTIC-CRITERIA; SYNOVIAL-FLUIDS; MESSENGER-RNA; CELLS; DISTINCT; MARKER; MS; INFLAMMATION;
D O I
10.1371/journal.pone.0061835
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Differences in cytokine/chemokine profiles among patients with neuromyelitis optica (NMO), relapsing remitting multiple sclerosis (RRMS), and primary progressive MS (PPMS), and the relationships of these profiles with clinical and neuroimaging features are unclear. A greater understanding of these profiles may help in differential diagnosis. Methods/Principal Findings: We measured 27 cytokines/chemokines and growth factors in CSF collected from 20 patients with NMO, 26 with RRMS, nine with PPMS, and 18 with other non-inflammatory neurological diseases (OND) by multiplexed fluorescent bead-based immunoassay. Interleukin (IL)-17A, IL-6, CXCL8 and CXCL10 levels were significantly higher in NMO patients than in OND and RRMS patients at relapse, while granulocyte-colony stimulating factor (G-CSF) and CCL4 levels were significantly higher in NMO patients than in OND patients. In NMO patients, IL-6 and CXCL8 levels were positively correlated with disability and CSF protein concentration while IL-6, CXCL8, G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IFN-gamma were positively correlated with CSF neutrophil counts at the time of sample collection. In RRMS patients, IL-6 levels were significantly higher than in OND patients at the relapse phase while CSF cell counts were negatively correlated with the levels of CCL2. Correlation coefficients of cytokines/chemokines in the relapse phase were significantly different in three combinations, IL-6 and GM-CSF, G-CSF and GM-CSF, and GM-CSF and IFN-gamma, between RRMS and NMO/NMOSD patients. In PPMS patients, CCL4 and CXCL10 levels were significantly higher than in OND patients. Conclusions: Our findings suggest distinct cytokine/chemokine alterations in CSF exist among NMO, RRMS and PPMS. In NMO, over-expression of a cluster of Th17-and Th1-related proinflammatory cytokines/chemokines is characteristic, while in PPMS, increased CCL4 and CXCL10 levels may reflect on-going low grade T cell and macrophage/microglia inflammation in the central nervous system. In RRMS, only a mild elevation of proinflammatory cytokines/chemokines was detectable at relapse.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Proteomics Comparison of Cerebrospinal Fluid of Relapsing Remitting and Primary Progressive Multiple Sclerosis
    Stoop, Marcel P.
    Singh, Vaibhav
    Dekker, Lennard J.
    Titulaer, Mark K.
    Stingl, Christoph
    Burgers, Peter C.
    Smitt, Peter A. E. Sillevis
    Hintzen, Rogier Q.
    Luider, Theo M.
    PLOS ONE, 2010, 5 (08):
  • [2] Distinct Serum Cytokine Profiles in Neuromyelitis Optica and Multiple Sclerosis
    Wang, Kai Chen
    Lee, Chao-Lin
    Chen, Shao-Yuan
    Chen, Jeen-Chen
    Yang, Chih-Wen
    Chen, Shyi-Jou
    Tsai, Ching-Piao
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2013, 33 (02) : 58 - 64
  • [3] Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis
    Hakansson, Irene
    Gouveia-Figueira, Sandra
    Ernerudh, Jan
    Vrethem, Magnus
    Ghafouri, Nazdar
    Ghafouri, Bijar
    Nording, Malin
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2018, 138 : 41 - 47
  • [4] Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6
    Uzawa, Akiyuki
    Mori, Masahiro
    Arai, Kimihito
    Sato, Yasunori
    Hayakawa, Sei
    Masuda, Saeko
    Taniguchi, Junko
    Kuwabara, Satoshi
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (12) : 1443 - 1452
  • [5] Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis
    Lee, Jingyun
    McKinney, Kimberly Q.
    Pavlopoulos, Antonis J.
    Han, May H.
    Kim, Su-Hyun
    Kim, Ho Jin
    Hwang, Sunil
    CLINICA CHIMICA ACTA, 2016, 462 : 118 - 126
  • [6] Serum level measurement of progranulin in relapsing-remitting multiple sclerosis and neuromyelitis optica patients
    Azadani, Niloufar Nasr
    Norouzi, Faezeh
    Hajizadeh, Mahsa
    Parsa, Sara
    Khalighinejad, Farnaz
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2019, 8 (03): : 16 - 20
  • [7] Absence of Neuromyelitis Optica IgG Antibody in an Active Relapsing-Remitting Multiple Sclerosis Population
    Smith, Craig. H.
    Waubant, Emmanuelle
    Langer-Gould, Annette
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2009, 29 (02) : 104 - 106
  • [8] Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis
    Rodrigues, Dora-Neide
    Paes, Renata Alves
    Ferreira Vasconcelos, Claudia Cristina
    Landeira-Fernandez, Jesus
    Papais Alvarenga, Regina Maria
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2011, 69 (04) : 590 - 595
  • [9] Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder
    Wang, Yuge
    Zhou, Yifan
    Sun, Xiaobo
    Lu, Tingting
    Wei, Lei
    Fang, Ling
    Chen, Chen
    Huang, Qiao
    Hu, Xueqiang
    Lu, Zhengqi
    Peng, Lisheng
    Qiu, Wei
    NEUROIMMUNOMODULATION, 2016, 23 (5-6) : 352 - 358
  • [10] Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis
    Novakova, Lenka
    Axelsson, Markus
    Khademi, Mohsen
    Zetterberg, Henrik
    Blennow, Kaj
    Malmestrom, Clas
    Piehl, Fredrik
    Olsson, Tomas
    Lycke, Jan
    JOURNAL OF NEUROCHEMISTRY, 2017, 141 (02) : 296 - 304